These findings suggest that the novel incretin analogs semaglutide and tirzepatide (administered as add-on treatment to insulin) have the potential to improve glucose control, reduce insulin requirements and promote weight management in AYA with T1D, without increasing the risk of serious adverse events [139]. The gene discussed is INS; the disease is type 1 diabetes mellitus.